Evidence map›Paper›PMID 42277542›Full record

Observational studyInternational journal of clinical oncology2026

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study.

Koichi Sugimoto, Shingo Toyoda, Lan Inoki, Keiichiro Mori, Takafumi Yanagisawa, Keita Tamura, Takuhisa Nukaya, Ryoichi Maenosono, Hirofumi Morinaka, Shingo Nishimura and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Koichi SugimotoDepartment of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan.
Shingo ToyodaDepartment of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan.
Lan InokiDepartment of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan.
Keiichiro MoriDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Takafumi YanagisawaDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Keita TamuraDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Takuhisa NukayaDepartment of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Ryoichi MaenosonoDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Hirofumi MorinakaDepartment of Urology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Shingo NishimuraDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Kensuke BekkuDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Kazumasa KomuraDepartment of Urology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Kiyoshi TakaharaDepartment of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Teruo InamotoDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Haruhito AzumaDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Kazutoshi FujitaDepartment of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan. kfujita@med.kindai.ac.jp.ORCID http://orcid.org/0000-0002-6774-7497
JK-FOOT study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitor (ICI)-based combination therapies, including immune checkpoint inhibitor plus immune checkpoint inhibitor (IO + IO) and immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO + TKI) regimens, have significantly improved outcomes in metastatic renal cell carcinoma (mRCC). However, the prognostic impact of host-related factors in patients receiving these therapies remains unclear.

methodsWe retrospectively analyzed 493 patients with mRCC treated with IO+IO (n = 205) or IO+TKI (n = 288) as first-line therapy. Survival outcomes and treatment responses were evaluated according to host-related factors using Cox proportional hazards models.

resultsIn the IO+IO cohort, multiple host-related factors were independently associated with worse overall survival, including BMI < 25 kg/m

conclusionThe prognostic impact of host-related factors differs according to treatment regimen in mRCC. These findings suggest that host immune and metabolic conditions play a more prominent role in immune-driven IO+IO therapy, whereas tumor-related factors may predominate in IO+TKI therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsProtein Kinase InhibitorsAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsProtein Kinase InhibitorsCombination therapyHost-related factorsImmune checkpoint inhibitorsMetastatic renal cell carcinomaPrognosis

Identifiers

PMID42277542
PMCPMC13401547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.